세계의 항체 치료제 시장 : 형태별, 질환 영역별, 투여 경로별, 최종사용자별, 지역별, 경쟁 상황 - 분석 및 예측(2024-2033년)

“Global Antibody Therapeutic Market Poised for Remarkable Growth.”

The global antibody therapeutic market occupies a pivotal role within the biopharmaceutical and life sciences sectors, dedicated to the manufacturing, advancement, and commercialization of antibodies with diverse applications in medical and research domains. These antibodies, or immunoglobulins, are essential proteins generated by the immune system, crucial for identifying and neutralizing harmful pathogens, toxins, and foreign substances. Within the market context, antibodies are produced, modified, and applied for a spectrum of purposes, encompassing diagnostics, therapeutics, and research endeavors, spanning disease detection and treatment to laboratory experiments and pharmaceutical development.

The expansion of the global antibody therapeutic markets was propelled by several influential factors. Primarily, the rising prevalence of chronic diseases and the escalating demand for targeted therapies have intensified the quest for innovative treatment modalities.

Market Segmentation:

Segmentation 1: by Disease Area

• Autoimmune and Inflammatory Disease
• Oncology
• Haematology
• Infectious Disease
• Osteology
• Immunology
• Neurology
• Others Disease Area

Segmentation 2: by Route of Administration

• Intravenous
• Subcutaneous
• Others Route of Administration

Segmentation 3: by End-User

• Hospitals
• Long term Care Facilities
• Others End-User

Segmentation 4: by Format

• Monoclonal Antibodies
• Polyclonal Antibodies
• Antibody Fragments
• Bispecific Antibodies
• Others Novel Antibody Therapies

Segmentation 5: by Region

• North America
• Europe
• Asia-Pacific
• Rest-of-the-World

Key Questions Answered:

• What are the growth opportunities for new entrants in the global antibody therapeutic sector?
• Who are the primary players operating within the global antibody therapeutics market?
• What key strategies are likely to be embraced by participants aiming to expand their share in the global antibody therapeutic industry?
• How is the competitive landscape shaping up in the global antibody therapeutics market?
• What emerging trends might impact the growth of the global antibody therapeutics market?
• Which product type segment is anticipated to demonstrate a substantial CAGR in the future?
• Which application segment is poised to capture a significant share in the global antibody therapeutic industry?
• Which region presents lucrative opportunities for manufacturers in the global antibody therapeutics market?

Table of Contents

Executive Summary

1. Markets

• 1.1. Trends: Current and Future Impact Assessment
  • 1.1.1. Sample Text
  • 1.1.2. Trend 1
  • 1.1.3. Trend 2
  • 1.1.4. Trend 3
• 1.2. Supply chain Overview
  • 1.2.1. Value Chain Analysis
  • 1.2.2. Market Map
• 1.3. Research and Development Review
  • 1.3.1. Patent Filing Trend (by Country, Company)
• 1.4. Regulatory Landscape
• 1.5. Impact Analysis for Key Global Events- COVID-19
• 1.6. Market Dynamics Overview
  • 1.6.1. Market Drivers
  • 1.6.2. Market Restraints
  • 1.6.3. Market Opportunities

2. Application

• 2.1. Application Segmentation
• 2.2. Application Summary
• 2.3. Global Antibody Therapeutic Market (By Disease Area)
  • 2.3.1. Autoimmune and Inflammatory Disease
  • 2.3.2. Oncology
  • 2.3.3. Haematology
  • 2.3.4. Infectious Disease
  • 2.3.5. Osteology
  • 2.3.6. Immunology
  • 2.3.7. Neurology
  • 2.3.8. Others Disease Area
• 2.4. Global Antibody Therapeutic Market (By Route of Administration)
  • 2.4.1. Intravenous
  • 2.4.2. Subcutaneous
  • 2.4.3. Others Route of Administration
• 2.5. Global Antibody Therapeutic Market (By End-User)
  • 2.5.1. Hospitals
  • 2.5.2. Long term Care Facilities
  • 2.5.3. Others End-User

3. Products

• 3.1. Product Segmentation
• 3.2. Product Summary
• 3.3. Global Antibody Therapeutic Market
  • 3.3.1. Market Overview
    • 3.3.1.1. Analyst View
• 3.4. Global Antibody Therapeutic Market (By Format)
  • 3.4.1. Monoclonal Antibodies
  • 3.4.2. Polyclonal Antibodies
  • 3.4.3. Antibody Fragments
  • 3.4.4. Bispecific Antibodies
  • 3.4.5. Others Novel Antibody Therapies

4. Regions

• 4.1. Regional Summary
• 4.2. Drivers and Restraints
• 4.3. North America
  • 4.3.1. Regional Overview
  • 4.3.2. Driving Factors for Market Growth
  • 4.3.3. Factors Challenging the Market
  • 4.3.4. Application
  • 4.3.5. Product
  • 4.3.6. U.S.
  • 4.3.7. U.S. Antibody Therapeutic Market by Application
  • 4.3.8. Canada
  • 4.3.9. Canada Antibody Therapeutic Market by Application
• 4.4. Europe
  • 4.4.1. Regional Overview
  • 4.4.2. Driving Factors for Market Growth
  • 4.4.3. Factors Challenging the Market
  • 4.4.4. Application
  • 4.4.5. Product
  • 4.4.6. Germany
  • 4.4.7. Germany Antibody Therapeutic Market by Application
  • 4.4.8. U.K.
  • 4.4.9. U.K. Antibody Therapeutic Market by Application
  • 4.4.10. France
  • 4.4.11. France Antibody Therapeutic Market by Application
  • 4.4.12. Rest of Europe
  • 4.4.13. Rest of Europe Antibody Therapeutic Market by Application
• 4.5. Asia Pacific
  • 4.5.1. Regional Overview
  • 4.5.2. Driving Factors for Market Growth
  • 4.5.3. Factors Challenging the Market
  • 4.5.4. Application
  • 4.5.5. Product
  • 4.5.6. China
  • 4.5.7. China Antibody Therapeutic Market by Application
  • 4.5.8. Japan
  • 4.5.9. Japan Antibody Therapeutic Market by Application
  • 4.5.10. India
  • 4.5.11. India Antibody Therapeutic Market by Application
  • 4.5.12. Rest-of-Asia-Pacific
  • 4.5.13. Rest-of-Asia-Pacific Antibody Therapeutic Market by Application
• 4.6. Rest-of-the-World (RoW)
  • 4.6.1. Regional Overview
  • 4.6.2. Driving Factors for Market Growth
  • 4.6.3. Factors Challenging the Market
  • 4.6.4. Application
  • 4.6.5. Product
  • 4.6.6. Latin America
  • 4.6.7. Latin America Antibody Therapeutic Market by Application
  • 4.6.8. The Middle East and Africa
  • 4.6.9. The Middle East and Africa Antibody Therapeutic Market by Application

5. Markets - Competitive Benchmarking & Company Profiles

• 5.1. Next Frontiers…..
• 5.2. Geographic Assessment
  • 5.2.1. Hoffmann-La Roche Ltd.
    • 5.2.1.1. Overview
    • 5.2.1.2. Top Products / Product Portfolio
    • 5.2.1.3. Top Competitors
    • 5.2.1.4. Target Customers
    • 5.2.1.5. Key Personnel
    • 5.2.1.6. Analyst View
    • 5.2.1.7. Market Share
  • 5.2.2. AbbVie, Inc
    • 5.2.2.1. Overview
    • 5.2.2.2. Top Products / Product Portfolio
    • 5.2.2.3. Top Competitors
    • 5.2.2.4. Target Customers
    • 5.2.2.5. Key Personnel
    • 5.2.2.6. Analyst View
    • 5.2.2.7. Market Share
  • 5.2.3. Amgen Inc.
    • 5.2.3.1. Overview
    • 5.2.3.2. Top Products / Product Portfolio
    • 5.2.3.3. Top Competitors
    • 5.2.3.4. Target Customers
    • 5.2.3.5. Key Personnel
    • 5.2.3.6. Analyst View
    • 5.2.3.7. Market Share
  • 5.2.4. Bristol-Myers Squibb Company
    • 5.2.4.1. Overview
    • 5.2.4.2. Top Products / Product Portfolio
    • 5.2.4.3. Top Competitors
    • 5.2.4.4. Target Customers
    • 5.2.4.5. Key Personnel
    • 5.2.4.6. Analyst View
    • 5.2.4.7. Market Share
  • 5.2.5. Johnson & Johnson Services, Inc.
    • 5.2.5.1. Overview
    • 5.2.5.2. Top Products / Product Portfolio
    • 5.2.5.3. Top Competitors
    • 5.2.5.4. Target Customers
    • 5.2.5.5. Key Personnel
    • 5.2.5.6. Analyst View
    • 5.2.5.7. Market Share
  • 5.2.6. Merck & Co., Inc.
    • 5.2.6.1. Overview
    • 5.2.6.2. Top Products / Product Portfolio
    • 5.2.6.3. Top Competitors
    • 5.2.6.4. Target Customers
    • 5.2.6.5. Key Personnel
    • 5.2.6.6. Analyst View
    • 5.2.6.7. Market Share
  • 5.2.7. Regeneron Pharmaceuticals Inc.
    • 5.2.7.1. Overview
    • 5.2.7.2. Top Products / Product Portfolio
    • 5.2.7.3. Top Competitors
    • 5.2.7.4. Target Customers
    • 5.2.7.5. Key Personnel
    • 5.2.7.6. Analyst View
    • 5.2.7.7. Market Share
  • 5.2.8. Novartis AG
    • 5.2.8.1. Overview
    • 5.2.8.2. Top Products / Product Portfolio
    • 5.2.8.3. Top Competitors
    • 5.2.8.4. Target Customers
    • 5.2.8.5. Key Personnel
    • 5.2.8.6. Analyst View
    • 5.2.8.7. Market Share
  • 5.2.9. AstraZeneca
    • 5.2.9.1. Overview
    • 5.2.9.2. Top Products / Product Portfolio
    • 5.2.9.3. Top Competitors
    • 5.2.9.4. Target Customers
    • 5.2.9.5. Key Personnel
    • 5.2.9.6. Analyst View
    • 5.2.9.7. Market Share
  • 5.2.10. Eli Lilly and Company
    • 5.2.10.1. Overview
    • 5.2.10.2. Top Products / Product Portfolio
    • 5.2.10.3. Top Competitors
    • 5.2.10.4. Target Customers
    • 5.2.10.5. Key Personnel
    • 5.2.10.6. Analyst View
    • 5.2.10.7. Market Share
  • 5.2.11. GlaxoSmithKline plc.
    • 5.2.11.1. Overview
    • 5.2.11.2. Top Products / Product Portfolio
    • 5.2.11.3. Top Competitors
    • 5.2.11.4. Target Customers
    • 5.2.11.5. Key Personnel
    • 5.2.11.6. Analyst View
    • 5.2.11.7. Market Share
  • 5.2.12. Takeda Pharmaceutical Company Ltd.
    • 5.2.12.1. Overview
    • 5.2.12.2. Top Products / Product Portfolio
    • 5.2.12.3. Top Competitors
    • 5.2.12.4. Target Customers
    • 5.2.12.5. Key Personnel
    • 5.2.12.6. Analyst View
    • 5.2.12.7. Market Share
  • 5.2.13. Abcam Plc.
    • 5.2.13.1. Overview
    • 5.2.13.2. Top Products / Product Portfolio
    • 5.2.13.3. Top Competitors
    • 5.2.13.4. Target Customers
    • 5.2.13.5. Key Personnel
    • 5.2.13.6. Analyst View
    • 5.2.13.7. Market Share
  • 5.2.14. Thermo Fisher Scientific, Inc
    • 5.2.14.1. Overview
    • 5.2.14.2. Top Products / Product Portfolio
    • 5.2.14.3. Top Competitors
    • 5.2.14.4. Target Customers
    • 5.2.14.5. Key Personnel
    • 5.2.14.6. Analyst View
    • 5.2.14.7. Market Share
  • 5.2.15. Cell Signaling Technology
    • 5.2.15.1. Overview
    • 5.2.15.2. Top Products / Product Portfolio
    • 5.2.15.3. Top Competitors
    • 5.2.15.4. Target Customers
    • 5.2.15.5. Key Personnel
    • 5.2.15.6. Analyst View
    • 5.2.15.7. Market Share

6. Research Methodology

• 6.1. Data Sources
  • 6.1.1. Primary Data Sources
  • 6.1.2. Secondary Data Sources
  • 6.1.3. Data Triangulation
• 6.2. Market Estimation and Forecast